Curaleaf stock clears key regulatory hurdles for Aurora bid

Curaleaf Holdings said on November 10, 2026, that it had received all required competition-law clearances for its proposed acquisition of Aurora Cannabis. The company said Germany and Canada were the only jurisdictions where clearance was required. The announcement was published in a Curaleaf press release.

Regulatory hurdle now cleared

Germany's Federal Ministry for Economic Affairs and Energy approved the proposed acquisition of voting rights in Aurora's German entities on October 20. Canada's Competition Bureau issued a no-action letter on November 2, and Germany's Federal Cartel Office said on November 3 that the transaction did not meet the conditions for prohibition.

Curaleaf's enhanced premium offer, launched on October 6, remains outstanding and is scheduled to expire on December 4, 2026, unless it is withdrawn or amended. The offer is still subject to conditions being satisfied or waived. Curaleaf said the completed reviews provide greater certainty of completion and support a faster path to closing.

Competing proposal remains relevant

Curaleaf is pursuing all outstanding common shares of Aurora while Organigram has proposed a separate acquisition of Aurora. The regulatory clearances remove one group of obstacles for Curaleaf, but shareholder decisions and the remaining transaction conditions continue to determine which proposal advances.

Curaleaf's international cannabis model

Curaleaf develops and sells consumer and medical cannabis products through brands including Curaleaf, Select, Grassroots, Find, Dark Heart and Anthem. Its operations cover medical and adult-use markets, with an international distribution network spanning Europe, Canada and Australasia. The company describes itself as a leading international provider, while Aurora Cannabis and Organigram are named cannabis peers in the competing Aurora transaction. Curaleaf's position is therefore tied to both its multi-market operating model and its ability to complete the proposed combination.

Canadian cannabis shares remain exposed to deal execution, regulatory developments and shareholder decisions across the sector; the S&P/TSX Composite market environment provides the broader Canadian equity backdrop.